Cardiovascular risk: who should we treat, and how much should we stratify?

Patel, Anushka
May 2009
Heart;May2009, Vol. 95 Issue 10, p783
Academic Journal
No abstract available.


Related Articles

  • Beyond hypertension: Toward guidelines for cardiovascular risk reduction* Volpe, Massimo; Alderman, Michael H.; Furberg, Curt D.; Jackson, Rodney; Kostis, John B.; Laragh, John H.; Psaty, Bruce M.; Ruilope, Luis M. // American Journal of Hypertension;Nov2004, Vol. 17 Issue 11, p1068 

    Most current clinical guidelines focus primarily on the management of individual cardiovascular risk factors, such as high blood pressure (BP), hypercholesterolemia, or diabetes. A more appropriate clinical approach to reducing cardiovascular disease risk would be based on a comprehensive...

  • National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Bakris, George; Vassalotti, Joseph; Ritz, Eberhard; Wanner, Christoph; Stergiou, George; Molitch, Mark; Nesto, Richard; Kaysen, George A.; Sowers, James R. // Kidney International;Oct2010, Vol. 78 Issue 8, p726 

    Cardiovascular disease (CVD) is the most common cause of death in industrialized nations. Type 2 diabetes is a CVD risk factor that confers risk similar to a previous myocardial infarction in an individual who does not have diabetes. In addition, the most common cause of chronic kidney disease...

  • WHO AND WHEN SHOULD WE TREAT FOR OSTEOPOROSIS?  // Osteoporosis International;Mar2006 Supplement 1, Vol. 17, pS27 

    The article presents the abstract for the research "Who and When Should We Treat Osteoporosis?".

  • Use of Chronic Kidney Disease to Enhance Prediction of Cardiovascular Risk in Those at Medium Risk. Chia, Yook Chin; Lim, Hooi Min; Ching, Siew Mooi // PLoS ONE;10/23/2015, Vol. 10 Issue 10, p1 

    Based on global cardiovascular (CV) risk assessment for example using the Framingham risk score, it is recommended that those with high risk should be treated and those with low risk should not be treated. The recommendation for those of medium risk is less clear and uncertain. We aimed to...

  • Pro: Cardiovascular calcifications are clinically relevant. Bover, Jordi; Evenepoel, Pieter; Ureña-Torres, Pablo; Vervloet, Marc G.; Brandenburg, Vincent; Mazzaferro, Sandro; Covic, Adrian; Goldsmith, David; Massy, Ziad A.; Cozzolino, Mario // Nephrology Dialysis Transplantation;Mar2015, Vol. 30 Issue 3, p345 

    It is increasingly acknowledged that mineral and bone disorders (MBDs) contribute to the excessively high cardiovascular (CV) disease morbidity and mortality observed in patients with chronic kidney disease (CKD). There is ongoing debate as to whether screening for CV calcification, one of the...

  • The metabolic syndrome: time for a critical appraisal. Kahn, R.; Buse, J.; Ferrannini, E.; Stern, M. // Diabetologia;Sep2005, Vol. 48 Issue 9, p1684 

    Background: The term ‘metabolic syndrome’ refers to a clustering of specific cardiovascular disease (CVD) risk factors whose underlying pathophysiology is thought to be related to insulin resistance. Methods: Since the term is widely used in research and clinical practice, we...

  • Longitudinal associations between BMI, waist circumference, and cardiometabolic risk in US youth: Monitoring implications. Jago, R.; Mendoza, J. A.; Chen, T.; Baranowski, T. // Obesity (19307381);Mar2013, Vol. 21 Issue 3, pE271 

    Objective: This study examined whether change in body mass index (BMI) or waist circumference (WC) is associated with change in cardiometabolic risk factors and differences between cardiovascular disease specific and diabetes specific risk factors among adolescents. We also sought to examine any...

  • Perioperative Blood Loss in Bipolar Hemiarthroplasty for Femoral Neck Fracture:Analysis of Risk Factors. Jai Hyung Park; Hyoung Soo Kim; Jeong Hyun Yoo; Joo Hak Kim; Ki Hyuk Sung; Joon Yub Kim; Sang Jun Park; In Hyeok Lee // Hip & Pelvis;Jun2013, Vol. 25 Issue 2, p110 

    Purpose: We compared visible blood loss and calculated blood loss after bipolar hemiarthroplasty in femoral neck fracture, and evaluated correlation between blood loss and its risk factors. Materials and Methods: A total of 356 patients who underwent bipolar hemiarthroplasty in femoral neck...

  • Lipid-Lowering Therapy With Statins in High-Risk Elderly Patients: The Treatment-Risk Paradox. Ko, Dennis T.; Mamdani, Muhammad; Alter, David A. // JAMA: Journal of the American Medical Association;4/21/2004, Vol. 291 Issue 15, p1864 

    Context The benefits of cardiovascular therapies such as statins for secondary prevention have been well documented, although they may not be optimally used in patients most likely to benefit. Ideally, aggressiveness in the use of these beneficial therapies should correlate with baseline...

  • The Metabolic Syndrome: Time for a Critical Appraisal. Kahn, Richard; Buse, John; Ferrannini, Ele; Stern, Michael // Diabetes Care;Sep2005, Vol. 28 Issue 9, p2289 

    The term "metabolic syndrome" refers to a clustering of specific cardiovascular disease (CVD) risk factors whose underlying pathophysiology is thought to be related to insulin resistance. Since the term is widely used in research and clinical practice, we undertook an extensive review of the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics